In the arena of solubility enhancement, several problems are encountered. A novel approach based on lipid drug delivery system has evolved, pharmacosomes. Pharmacosomes are colloidal, nanometric size micelles, vesicles or may be in the form of hexagonal assembly of colloidal drug dispersions attached covalently to the phospholipid. They act as befitting carrier for delivery of drugs quite precisely owing to their unique properties like small size, amphiphilicity, active drug loading, high entrapment efficiency, and stability. They help in controlled release of drug at the site of action as well as in reduction in cost of therapy, drug leakage and toxicity, increased bioavailability of poorly soluble drugs, and restorative effects. There has been advancement in the scope of this delivery system for a number of drugs used for inflammation, heart diseases, cancer, and protein delivery along with a large number of herbal drugs. Hence, pharmacosomes open new challenges and opportunities for improved novel vesicular drug delivery system. 1. Introduction The novel drug delivery system has been exploited a lot in the past few decades, and attention is also being paid to further develop this system. The two ideal requirements for a system to be novel are(1)drug delivery at a predetermined rate and for pre-determined span of time;(2)conveying the active entity to the target site.At this point of time, there is no such system that can fulfil all these requirements. So a lot of efforts are required to accomplish them using novel approaches. These goals are being achieved by concentrating attention either on drug distribution by unifying drug into a carrier system, modifying molecular drug construct, or by restraining drug release in the bioenvironment to ascertain assigned distribution profile. Novel drug delivery attempts to minimize the side effects and maintain relatively unvarying and potent levels of drug in the body. The carriers or chemical derivatization may help to localize the drug action spatially in diseased tissue or organ or adjacent to it [1]. Among the different pharmaceutical carriers (Figure 1), the vesicular carriers are extremely organized assemblies of bilayers of lipid that may be single or concentric in nature formed when the building blocks (amphipathic) of these bilayers encounter water [2]. The clinical use of many drugs particularly chemotherapeutic agents is limited because of their narrow therapeutic window [1]. So the novel approaches in drug delivery serve as a helping hand to achieve all these imperative goals. Figure 1: Different
References
[1]
J. L. Patel and P. D. Bharadia, “A review on: pharamacosomes as a novel vesicular drug delivery system,” WJPR, vol. 1, pp. 456–469, 2012.
[2]
K. De Pintu and De Arnab, “Pharmacosomes: a potential drug delivery system,” International Research Journal of Pharmacy, vol. 3, pp. 102–105, 2012.
[3]
S. Saraf, R. Rathi, C. D. Kaur, and S. Saraf, “Colloidosomes an advanced vesicular system in drug delivery,” Asian Journal of Scientific Research, vol. 4, no. 1, pp. 1–15, 2011.
[4]
A. Deepti, R. Madhukar, R. Jukanti, B. Suresh, P. Reddy, and V. Reddy, “Provesicular drug delivery systems: an overview and appraisal,” Scholars Research Library, vol. 2, no. 4, pp. 135–146, 2010.
[5]
R. K. Kesarvani, A. K. Sharma, M. D. Ayaz, and R. K. Kesharwani, “Review novel drug delivery system for the vesicular delivery of drug by the niosomes,” International Journal of Research in Controlled Release, vol. 1, pp. 1–8, 2011.
[6]
S. Gupta, R. P. Singh, P. Lokwani, S. Yadav, and S. K. Gupta, “Vesicular system as targeted drug delivery system: an overview,” International Journal of Pharmacy and Technology, vol. 3, no. 2, pp. 987–1021, 2011.
[7]
R. C. Doijad, D. S. Bhambere, M. V. Fakirappa, and N. V. Deshmukh, “Formulation and characterization of vesicular drug delivery system for anti-HIV drug,” Journal of Global Pharma Technology, vol. 1, no. 1, pp. 94–100, 2009.
[8]
M. J. Pozansky and R. L. Juliano, “Biological approaches to the controlled delivery of drugs: a critical review,” Pharmacological Reviews, vol. 36, no. 4, pp. 277–336, 1983.
[9]
A. D. Bangham, M. M. Standish, and G. Weissmann, “The action of steroids and streptolysin S on the permeability of phospholipid structures to cations,” Journal of Molecular Biology, vol. 13, no. 1, pp. 253–259, 1965.
[10]
U. Ogihara, T. Sasaki, H. Toyama, O. M. Sneha, and H. Nishigori, “Rapid diagnostic imaging of cancer using radiolabeled liposomes,” Cancer Detection and Prevention Journal, vol. 21, pp. 490–496, 1997.
[11]
D. Kavitha, J. Naga Sowjanya, and S. Panaganti, “Pharmacosomes: an emerging vesicular system,” International Journal of Pharmaceutical Sciences Review and Research, vol. 5, no. 3, pp. 168–171, 2010.
[12]
S. Biju, S. Talegaonkar, P. Mishra, and R. Khar, “Vesicular systems: an overview,” Indian Journal of Pharmaceutical Sciences, vol. 71, pp. 421–427, 2009.
[13]
M. P. Wagh and J. S. Patel, “Biopharmaceutical classification system: scientific basis for biowaiver extensions,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 1, pp. 12–19, 2010.
[14]
R. L？benberg and G. L. Amidon, “Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 3–12, 2000.
[15]
J. Varshosaz, R. Talari, S. A. Mostafavi, and A. Nokhodchi, “Dissolution enhancement of gliclazide using in situ micronization by solvent change method,” Powder Technology, vol. 187, no. 3, pp. 222–230, 2008.
[16]
V. E. Ivanov, Y. S. Moshkovskii, and L. M. Raikhman, “Effects of temperature on cascade systems of pharmacosome fusion,” Pharmaceutical Chemistry Journal, vol. 15, no. 9, pp. 619–621, 1981.
[17]
M. K. Rawat, A. Jain, and S. Singh, “In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats,” Journal of Pharmaceutical Sciences, vol. 100, no. 6, pp. 2406–2417, 2011.
[18]
N. K. Jain, Advances in Controlled and Novel Drug Delivery, CBS, 2003.
[19]
S. Sharma, L. Mishra, I. Grover, A. Gupta, and K. Kaur, “Liposomes: vesicular system an overview,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 4, pp. 15–21, 2010.
[20]
A. Semalty, M. Semalty, B. S. Rawat, D. Singh, and M. S. M. Rawat, “Pharmacosomes: the lipid-based new drug delivery system,” Expert Opinion on Drug Delivery, vol. 6, no. 6, pp. 599–612, 2009.
[21]
A. Semalty, M. Semalty, B. S. Rawat, D. Singh, and M. S. M. Rawat, “Development and evaluation of pharmacosomes of aceclofenac,” Indian Journal of Pharmaceutical Sciences, vol. 72, no. 5, pp. 576–581, 2010.
[22]
A. Steve, “Lipophilic drug derivatives for use in liposomes,” US Patent S, 534, 499, (C1 S14-25, A61K31/70), 1996.
[23]
I. Taskintuna, A. S. Banker, M. Flores-Aguilar et al., “Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis,” Retina, vol. 17, no. 1, pp. 57–64, 1997.
[24]
F. Franceschi and A. Giori, A Phospholipid Complex of Olive Fruits or Leaves Extracts Having Improved Bioavailability, EP1844785, 2007.
[25]
F. Di Pierro, Compositions Comprising Gingko Biloba Derivatives for the Treatment of Asthmatic and Allergic Conditions, EP1813280, 2007.
[26]
T. Doering, A. Traeger, and M. Waldmann-Laue, Cosmetic and Dermatological Composition For the Treatment of Aging or Photodamaged Skin, EP1640041, 2006.
[27]
E. Bombardelli, G. F. Patri, and R. Pozzi, Complexes of Saponins With Phospholipids and Pharmaceutical and Cosmetic Compositions Containing Them, EP0283713, 1988.
[28]
H. K. Kleinman and A. L. Goldstein, Treatment of skin, and wound repair, with thymosin beta-4, U.S Patent No- 20070015698, 2007.
[29]
H. K. Kleinman and A. L. Goldstein, Treatment of skin, and wound repair, with thymosin beta 4, U.S.PatentNo-20070015698, 2007, Khare A B, Soluble isoflavone compositions, WO/2004/ 045541, 2004.
[30]
G. Merizzi, An Anti-Oxidant Preparation Based on Plant Extracts for the Treatment of Circulation and Adiposity Problems, EP1214084, 2002.
[31]
M. O. Vaizoglu and P. P. Speiser, “Pharmacosomes—a novel drug delivery system,” Acta Pharmaceutica Suecica, vol. 23, no. 3, pp. 163–172, 1986.
[32]
I. P. Kaur and M. Kanwar, “Ocular preparations: the formulation approach,” Drug Development and Industrial Pharmacy, vol. 28, no. 5, pp. 473–493, 2002.
[33]
A. Semalty, M. Semalty, D. Singh, and M. S. M. Rawat, “Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery,” Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol. 67, no. 3, pp. 253–260, 2010.
[34]
M. J. Lawrence, “Surfactant systems: their use in drug delivery,” Chemical Society Reviews, vol. 23, no. 6, pp. 417–424, 1994.
[35]
C. C. Muller-Goymann and H.-J. Hamann, “Pharmacosomes—multilamellar vesicles consisting of pure drug,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 37, no. 2, pp. 113–117, 1991.
[36]
J. S. Valentino and N. C. William, Lymphatic Transport of Drugs, CRC Press, Boca Raton, Fla, USA, 1992.
[37]
A. Singh and R. Jain, “Targeted Vesicular Constructs for cryoprotection and treatment of H.Pylori infections,” US Patent 6576, 625, 2003.
[38]
Y. Li, D. J. Yang, S. L. Chen, S. B. Chen, and A. S. C. Chan, “Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods,” Pharmaceutical Research, vol. 25, no. 3, pp. 563–577, 2008.
[39]
E. Bombardelli and M. Spelta, “Phospholipid-polyphenol complexes: a new concept in skin care ingredients,” Cosmetics & Toiletries, vol. 106, pp. 69–76, 1991.
[40]
E. P. Goldberg, Targeted Drugs, Wiley Newyork, 1983.
[41]
A. Ping, Y. Jin, and C. Da-wei, “Preparation and in vivo behaviour of didanosinepharmacosomes in rats,” Journal of Chinese Pharmaceutical, vol. 3, pp. 227–235, 2005.
[42]
S. K. P. Rajapati, S. Kumar, V. K. Sahu, and G. Prakash, “Proniosomal gel of flurbiprofen: formulation and evaluation,” Journal of Drug Delivery and Therapeutics, vol. 2, no. 1, pp. 105–114, 2012.
[43]
S. P. Vyas, V. Jaitely, and P. Kanaujia, “Synthesis and characterisation of palymitoyl propanolol hydrochloride auto-lymphotrophs for oral administration,” International Journal of Pharmaceutics, vol. 186, no. 2, pp. 177–189, 1999.
[44]
P.-F. Yue, Q. Zheng, B. Wu et al., “Process optimization by response surface design and characterization study on geniposide pharmacosomes,” Pharmaceutical Development and Technology, vol. 17, no. 1, pp. 94–102, 2012.
[45]
A. B. Khare, “Soluble isoflavone compositions,” WO/2004/045541, 2004.
[46]
H. A. Lieberman, M. M. Rieger, and G. S. S. Banker, Pharmaceutical Dosage Forms: Disperse Systems, Informa Healthcare, London, UK, 1998.
[47]
B. M. Mithal, Ocular Dosage Forms, Text Book of Pharmaceutical Formulations, VallabhPrakashan, New Delhi, India, 1997.
[48]
F. La Torre and A. P. Nicolal, “Amikacin gel administration in the treatment of peristomal dermatitis,” Drugs under experimental and clinical research, vol. 24, no. 3, pp. 153–157, 1998.
[49]
L. M. Raikhman, Y. S. Moshkovskii, and L. A. Piruzyan, “Pharmacosome concept: a new approach to drug preparation,” Pharmaceutical Chemistry Journal, vol. 12, no. 4, pp. 431–434, 1978.
[50]
A. Semalty, M. Semalty, D. Singh, and M. S. M. Rawat, “Development and physicochemical evaluation of pharmacosomes of diclofenac,” Acta Pharmaceutica, vol. 59, no. 3, pp. 335–344, 2009.
[51]
M. Han, J. Chen, S. Chen, and X. Wang, “Preparation and study in vitro of 20(S) protopanaxadiolpharmacosomes,” China Journal of Pharmaceutics, vol. 35, pp. 842–846, 2010.
[52]
Z.-R. Zhang, J.-X. Wang, and J. Lu, “Optimization of the preparation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes using central composite design,” Yaoxue Xuebao, vol. 36, no. 6, pp. 456–461, 2001.
[53]
J. Yi-Guang, A. I. Ping, L. I. Miao, and H. Xin-Pu, “Preparation and properties of Acyclovir pharmacosomes,” Chinese Journal of Pharmaceuticals, vol. 36, no. 10, pp. 617–620, 2005.
[54]
S. Shalini and R. K. Roy, “Phytosomes: an emerging technology,” International Journal of Pharmaceutical Research and Development, vol. 2, pp. 14–15, 2010.
[55]
P. Shivanand and P. Kinjal, “Phytosomes: technical revolution in phytomedicine,” International Journal of PharmTech Research, vol. 2, no. 1, pp. 627–631, 2010.
[56]
E. Bombardelli and G. Mustich, “bilobalidephosphalipid complex, their uses and formulation containing them,” U.S. Patent No. EPO-275005 ,1991.
[57]
D. Murray, “Phytosomes-increase the absorption herbal extract,” http://doctormurray.com/phytosomes-herbal-support-increase-the-absorption-of-herbal-extracts/.
[58]
C. Marena and M. Lampertico, “Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders,” Planta Medica, vol. 57, no. 2, pp. A124–A125, 1991.
[59]
N. S. Chauhan, R. Gowtham, and B. Gopalkrishna, “Phytosomes: a potential Phytophospholipid carriers for herbal drug delivery,” Journal of Pharmacy Research, vol. 2, pp. 1267–1270, 2009.
[60]
N. K. Jain, Controlled and Novel Drug Delivery, CBS, New York, NY, USA, 1st edition, 2005.
[61]
A. Semalty, M. Semalty, and M. S. Rawat, “The Phytophospholipid complexes phytosomes: a potential therapeutic approach for hepatoprotective drug delivery,” Pharmacognosy Review, vol. 1, no. 2, pp. 369–374, 2007.
[62]
A. D. Kingom, “Pharmacognosy in 21 st century,” The Journal of Pharmacy and Pharmacology, vol. 53, no. 2, pp. 135–148, 2001.
[63]
B. Gabetta, E. Bombardelli, and G. Pifferi, “Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions,” U. S. Patent no-4764508, 1986.
[64]
E. Bombardelli, M. Spelta, R. Della Loggia, S. Sosa, and A. Tubaro, “Aging skin: protective effect of Silymarin-phytosome,” Fitoterapia, vol. 62, no. 2, pp. 115–122, 1991.
[65]
E. Bombardelli, A. Cristoni, and P. Morazzoni, “Phytosomes in functional cosmetics,” Fitoterapia, vol. 65, no. 5, pp. 387–401, 1994.
[66]
S. Sharma and M. Sikarwar, “Phytosome: a review,” Plant Indica, vol. 1, pp. 1–3, 2005.
[67]
S. Bhattacharya, “Phytosomes: emerging strategy in delivery of herbal drugs and nutraceuticals,” Pharma Times, vol. 41, no. 3, pp. 9–12, 2009.
[68]
S. Bhattacharya, “Phytosomes: the new technology for enhancement of bioavailability of botanicals and nutraceuticals,” International Journal of Health Research, vol. 2, no. 3, pp. 225–232, 2009.
[69]
P. M. Kidd, PHYTOSOMES, Highly Bioavailable Plant Extracts, http://www.dockidd.com/pdf/2LinksPhytosomeInd,5_10_04.pdf.
[70]
A. Joshi, S. Chaturvedi, and V. Kumar, Phytosomes-A Revolution in Herbal Drugs, Pharma Review, Kongposh publications, 2008.
